Chronic inflammatory disorders are often associated with an increased cancer risk. A particularly striking example of the chronic inflammationcancer link is seen in inflammatory bowel disease, in which chronic colitis or persistent inflammation in the colon is associated with elevated risk of colorectal cancer. Animal models exploring the mechanisms by which inflammation increases the risk of colon cancer have shown that inflammatory cells, through the effects of the cytokines they produce, have a major role in promoting neoplastic transformation. In this issue of the JCI, Popivanova and colleagues demonstrate that TNF-α, through its effects on the immune system, plays a critical role in promoting neoplastic transformation in this setting (see the related article beginning on page 560). Importantly, the study also provides evidence that anti-TNF-α therapies, which are currently in clinical use, may interrupt the process.
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The authors have declared that no conflict of interest exists. CD is a more varied disorder, which can affect essentially any segment of the gastrointestinal tract, with a preference for the terminal ileum (2). While UC causes inflammation restricted to the mucosa, CD is associated with granulomatous features and transmural inflammation that can be complicated by intestinal wall fibrosis and stenosis, internal and external fistulas, and intra-abdominal infections. The involvement of the colon and rectum, irrespective of the subtype of IBD, increases the risk for colorectal cancer (CRC), and the risk is more pronounced with early onset of the disease and greater severity and greater extent of the colitis (3). In fact, though patients with colitis-associated cancer (CAC) represent only about 1% of CRC cases, colitis patients are among those in the population at greatest risk of CRC. In patients with prolonged (>20 years) and extensive colitis involving the entire organ, the risk of CRC approaches 20%. Certain subsets of patients, such as those that have concurrent inflammation in the biliary tract (termed "primary sclerosing cholangitis"), have an even greater lifetime risk of CRC, approaching 50% (3). The abnormal inflammatory response observed in IBD is thought to require the interplay between host genetic factors and the intestinal microbiota (4). Indeed, some patients with IBD seem to improve upon antibiotic treatment, and multiple animal models of colitis are ameliorated by the administration of antibiotics or placement of animals in germ-free conditions (4) . Recently, the demonstration that a subset of CD patients carries mutations in the nucleotide-binding oligomerization domain-containing 2 (NOD2) gene (5-7), which encodes an intracellular pattern-recognition receptor for bacterial muramyldipeptides (4, 8) , bolsters the notion that an abnormal balance in the immune response to gut bacteria may be a central and general feature in IBD.
CAC: a paradigm for inflammationassociated cancer
As noted above, though CAC represents only a small fraction of the overall burden of CRC (3), the molecular pathogenesis of CAC likely represents a paradigm for inflammation-associated carcinogenesis. Adding to the particular interest in CAC has been the development of an animal model that reproducibly leads to colonic neoplasia in the setting of colitis. This model involves the administration of small doses of the carcinogen azoxymethane (AOM), followed by repeated rounds of chemical colitis induced by administration of dextran sulfate sodium (DSS) in the drinking water. By the end of three cycles of colitis, or in about 1-2 months of treatment, nearly 100% of mice develop neoplasms in the colon (9) .
Regardless of the specific inciting events underlying human IBD, a feature that is nearly always observed is the mucosal activation of NF-κB (10), a pleiotropic transcription factor with a key role in innate and adaptive immunity (11) . NF-κB is required for the expression of various proinflammatory factors (11), including mediators that play a critical role in IBD such as cytokines and adhesion molecules (2, 4) . Indeed, blockade of NF-κB can ameliorate or prevent the development of colitis in animal models (12) (13) (14) (15) . In addition to its critical function in inflammation, NF-κB promotes expression of a number of prosurvival factors and can play an oncogenic role in certain settings, especially in lymphoid malignancies (16) . More recently, attention has shifted to the potential role of NF-κB and mediators that activate NF-κB in inflammation-associated cancers.
NF-κB: a key player in CAC
NF-κB function is regulated by inhibitor of NF-κB (IκB) proteins, which prevent nuclear accumulation and DNA binding by NF-κB (11) . The turnover of IκB protein is dynamically regulated in response to various stimuli, including proinflammatory cytokines, microbial products, and various forms of cellular stress including DNA damage (11) . Ubiquitination and proteasomal degradation of IκB is activated by its phosphorylation, and the kinase responsible is a component of a multimeric complex known as the IκB kinase (IKK) (11) . Consistent with the proposed key role of IKK in regulating IκB and NF-κB, genetic inactivation of the IKKβ subunit in mice abrogates NF-κB activation in response to most stimuli (11) . Moreover, work from Greten, Karin, and colleagues showed that in the AOM/DSS model tissue-specific inactivation of IKKβ in the intestinal epithelium dramatically reduced tumor multiplicity, indicating that prosurvival signals provided by NF-κB probably play a role in colitisassociated tumor initiation (17) . On the other hand, this same study reported that deletion of IKKβ in the myeloid compartment, which greatly impairs most innate immune responses observed, had no significant effect on tumor number but did have a major effect on tumor size (17) . This latter observation indicates NF-κB activation in the immune compartment is important for tumor growth, probably via effects on the expression of certain cytokines, which might in turn have trophic effects on the outgrowth and/or progression of neoplastic colon cancer cells. In fact, modulation of IL-6 expression has a dramatic effect on tumor growth in experimental models of CAC, suggesting that this cytokine functions as a trophic factor for neoplastic epithelium (18) .
Figure 1
Role of TNF-α in inflammation associated with colorectal carcinogenesis. Injury to the intestinal epithelium can result in DNA damage and altered gene expression and function, the initial step required for neoplastic transformation. In addition, this is accompanied by activation of NF-κB within epithelial cells, which promotes prosurvival pathways that are required for the initial growth of the resulting neoplastic cells. NF-κB activation also promotes proinflammatory gene expression. TNF-α originating from the mucosa or possibly the epithelium itself, participates in orchestrating the activation of immune cells. Production of various proinflammatory factors by the activated immune system participates in the ensuing inflammatory response but additionally plays a role in tumor growth by providing trophic signals to the early neoplastic lesions. Loss of TNF-α signaling in immune cells, and not the mucosa, stops this cascade by aborting the mucosal inflammatory response, and this can be achieved by pharmacologic blockade of TNF-α with etanercept and possibly other agents (21) .
Other pathways that modulate NF-κB activation have been found to also play a role in the AOM/DSS experimental colitis model. Deficiency of the cylindromatosis (CYLD) gene, which encodes a deubiquitinase with an important role in regulating NF-κB activation, results in a tumor-susceptibility syndrome in humans known as cylindromatosis (19) . Inactivation of the murine homolog of CYLD enhances CAC formation in the setting of experimental colitis in mice (20) , indicating once again that activation of NF-κB in the setting of colitis is important to tumorigenesis.
TNF-α: a link between the immune response and cancer
The study from Popivanova and colleagues in this issue of the JCI extends this paradigm by examining the role of TNF-α in tumor progression in the AOM/DSS model of CAC (21) . TNF-α has previously been implicated in the development of colitis, and indeed pharmacologic blockade of TNF-α with monoclonal antibodies has demonstrated great efficacy in the treatment of IBD patients (22) . TNF-α has also been implicated as a positive factor in the development of some other epithelial malignancies, particularly skin cancer in mice (23) , raising the possibility that TNF-α may play a similar tumor-promoting role in CAC. In light of the prior data on TNF-α, Popivanova et al. examined the specific contribution of TNF-α signaling in CAC, using mice deficient in type I TNF receptor p55 (TNF-Rp55) (21) . Akin to what is observed in humans with IBD, abrogation of TNF signaling in mice greatly ameliorated their colitis, as could be gleaned from the decreased tissue injury, inflammatory cell infiltrates, and cytokine expression in the mucosa. Loss of TNF signaling also greatly suppressed CAC. The decreased likelihood of CAC, as a result of TNF receptor deficiency, was recapitulated in wild-type animals by pharmacologic inhibition of TNF-α with etanercept, a recombinant fusion protein resuling from fusion between the Fc portion of human IgG and the ligand-binding region of the TNF type I receptor.
TNF-α activates an oncogenic immune response
In light of the participation of epithelial cells and inflammatory cells in the tumorigenic process, the identification of the cell population that responds to TNF-α and that promotes tumor formation was very important to address. In elegant bone marrow chimeric studies, Popivanova et al. (21) found that the deficiency of TNF-Rp55 was only relevant when it involved immune system cells and not when it involved the epithelium. This indicates that TNF-α production in the mucosa, presumably initiated by resident cells, is required for activation of immune cells, which in turn are important in the subsequent development of cancer (Figure 1) . TNF-α did not appear to behave as a trophic factor for the epithelium, but was needed to activate a tumor-promoting immune response. In addition, an intriguing result reported by Popivanova et al., albeit one that lacks clear mechanistic insights at present, was the authors' finding that TNF-α blockade by etanercept may have had inhibitory effects on the outgrowth and/or persistence of neoplastic colon epithelial cells harboring β-catenin mutations. Mutational defects abrogating regulation of β-catenin signaling (e.g., adenomatous polyposis coli gene inactivation) have been suggested to be a late event in the pathogenesis of CAC in humans (24) . As such, it remains to be determined whether the association that Papivanova et al. observed between TNF blockade and a reduced β-catenin mutation frequency in neoplastic lesions in the mice reflects a direct stimulatory interaction between TNF signaling and β-catenin or the fact that loss of TNF signaling inhibited progression of neoplastic cells to the state at which they might acquire β-catenin dysregulation.
In closing, it is worth emphasizing that the observations reported in the Popivanova et al. (21) study have potentially significant clinical ramifications. While etanercept is approved for clinical use for rheumatoid arthritis, it lacks the efficacy that monoclonal antibodies against TNF have in inducing clinical remission in IBD. Nevertheless, it is likely that monoclonal antibodies against TNF would recapitulate the effect of etanercept in this model. Given the time course for development of CAC in humans, it will be some time before we know whether TNF blockade has a significant effect on inhibiting tumor formation in IBD patients, but the rationale for the potential efficacy of TNF blockade in CAC is now well supported by the findings in the current study. 
